[SCHEDULE 13G/A] Silexion Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.

Positive

• Full disclosure of stake: Reports 109,432 shares, equal to 4.9% of the class, providing transparency to the market
• Clear statement of passive intent: Certification that shares were not acquired to influence control
• Warrant exercise limiter: The 4.99% Blocker prevents inadvertent crossing of the 5% threshold, reducing governance uncertainty

Negative

• Concentrated near 5% threshold: Ownership at 4.9% is close to the 5% reporting threshold, which may complicate future increases in position
• Warrants excluded from percentage: 153,068 warrants exist but are not exercisable above the blocker, limiting flexibility to increase ownership

Insights

Securities Analyst

TL;DR: A passive 4.9% stake with a strict exercise blocker limits potential control or influence.

Orca Capital AG discloses a sub-5% passive stake, which under SEC rules typically signals non-controlling intent. The separate warrant position of 153,068 shares is contractually constrained by the 4.99% blocker, preventing conversion that would push ownership above the regulatory threshold. For investors, this is a straightforward disclosure of a meaningful minority position without apparent intent to exert control; it also limits immediate upside from warrant exercise due to the blocker.

Corporate Governance Expert

TL;DR: Filing shows compliance and clarity on voting/dispositive authority and the legal exercise limit on warrants.

The Schedule 13G/A cleanly separates sole voting and dispositive powers (both 109,432) and indicates no shared powers or group affiliations. The certification asserts passive ownership and no action to change control. The explicit 4.99% exercise restriction reduces regulatory and governance risk that might arise from sudden stake increases, but it also means potential dilution or change in influence is contractually limited.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Silexion Therapeutics Corp

(Name of Issuer)

Ordinary Shares, par value $0.0135 per share

(Title of Class of Securities)

G1281K130

(CUSIP Number)

09/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G1281K130

1

Names of Reporting Persons

Orca Capital AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 109,432.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 109,432.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

109,432.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 2,123,892 Ordinary Shares outstanding immediately after giving effect to the completion of the Issuer's registered offering and excludes 153,068 Ordinary Shares issuable upon the exercise of warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the warrants, as described in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on September 12, 2025, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Ordinary Shares (the "4.99% Blocker").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silexion Therapeutics Corp
(b)	Address of issuer's principal executive offices: 12 Abba Hillel Road, Ramat Gan, Israel 5250606
Item 2.
(a)	Name of person filing: Orca Capital AG
(b)	Address or principal business office or, if none, residence: Sperlring 2 85276 Hettenshausen Deutschland
(c)	Citizenship: Germany
(d)	Title of class of securities: Ordinary Shares, par value $0.0135 per share
(e)	CUSIP No.: G1281K130
Item 4.	Ownership
(a)	Amount beneficially owned: 109,432
(b)	Percent of class: 4.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 109,432
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 109,432
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orca Capital AG

Signature:	/s/ Thomas Konig
Name/Title:	Thomas Konig/Director
Date:	09/15/2025

FAQ

How many Silexion Therapeutics (SLXNW) shares does Orca Capital AG own?

Orca Capital AG beneficially owns 109,432 ordinary shares, representing 4.9% of the class.

Does Orca Capital have voting control over its reported SLXNW shares?

Yes. The filing reports sole voting power and sole dispositive power over the 109,432 shares.

Are there warrants associated with Orca's position in Silexion?

Yes. Orca holds warrants for 153,068 ordinary shares, but a contractual 4.99% blocker prevents exercising them if it would raise beneficial ownership above 4.99%.

Is Orca Capital acting to change or influence control of Silexion?

No. The filing includes a certification stating the securities were not acquired to change or influence control of the issuer.

Is Orca part of a group reporting combined ownership?

No. The filing indicates Orca Capital AG is not reporting as part of a group and reports no shared voting or dispositive power.